Posted on

MINDCURE Successfully Completes First Stage of Manufacturing Synthetic Ibogaine for Use in Psychedelic Clinical Research

By manufacturing ibogaine, MINDCURE’s research team will have access to a predictable and standardized supply of synthetic ibogaine while ensuring consistent dosing and reliable results.

‍
VANCOUVER, BC, June 3, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology and research for psychedelics, is pleased to announce that it has completed the first stage of manufacturing pharmaceutical grade ibogaine to be used in clinical research. Throughout this proof-of-concept stage, MINDCURE completed the chemistry and route scouting and successfully manufactured synthetic ibogaine.

In the coming weeks, MINDCURE will focus on the scale-up process by launching stage two of the manufacturing process for pharmaceutical grade ibogaine. During this stage, the Company will be running financial models while assessing the quality of the synthetic ibogaine when produced at scale in order to determine the timing of and economic viability for commercial-scale manufacturing.

As we ensure a disciplined approach to our leadership in psychedelics and commitment to value creation, MINDCURE recognizes the value of the iboga plant as a rare and diminishing resource. By manufacturing synthetic ibogaine, MINDCURE’s research team will have access to a sustainable and high-quality drug supply, ensuring consistent dosing and reliable results. Furthermore, the Company is creating the opportunity for synthetic ibogaine to be used by researchers conducting clinical trials and, eventually, by clinicians providing psychedelic therapy.

“We have successfully completed the critical first step in our goal of manufacturing synthetic ibogaine at a commercial scale for research purposes,” said Kelsey Ramsden, President and CEO of MINDCURE. “Ibogaine offers incredible therapeutic potential to treat addiction and shows promise in addressing other brain injuries, and we are very excited about the potential to manufacture and provide a high-quality synthetic product for promising research avenues, without impacting the natural supply of this amazing psychedelic that needs to be protected.”

Ibogaine has unique and broad actions in the brain, affecting multiple receptors and neurotransmitter systems. In addition to inducing powerful subjective effects, research indicates ibogaine may help repair and rewire addiction-related neural pathways. Emerging evidence of its neuroprotective effects, as well as its ability to boost brain neurotrophic factors and neuroplasticity processes, supports future research into the use of ibogaine and derivatives thereof for other indications, including in the treatment of neuropathic pain and neurodegenerative conditions, such as Parkinson’s and Alzheimer’s disease. While ibogaine showcases a wide mechanism of action, potential toxicity, and low bioavailability, which may preclude its usefulness in treating neurodegenerative disorders, MINDCURE will dutifully design any research efforts in recognition of these facts.

In addition to this news, the Company also announces it has granted a total of 10,000 stock options to certain employees or consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.38 per share and subject to the terms of the Plan.

About Mind Cure Health Inc.

MINDCURE is a life sciences company focused on innovating and commercializing new ways to promote healing and improve mental health. The company is developing digital therapeutics technology and researching psychedelic compounds to support access to safe, evidence-based psychedelic-assisted therapies globally. Learn more at mindcure.com, and follow us on Facebook, Twitter, and Instagram.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business.  Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results, performance or achievements contemplated by forward-looking statements made may be materially different from the results anticipated or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the company’s ability to successfully develop, manufacture and commercialize pharmaceutical grade ibogaine to be used in clinical research.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; that the company will be successful in developing, manufacturing and commercializing ibogaine; and that Mind Cure will be able to operate its business as planned.

Although Mind Cure has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Mind Cure does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

Dr. Joel Raskin, a leader in psychiatry and neuroscience drug development, joins MINDCURE as Chief Medical Officer

Dr. Raskin is a psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization.

VANCOUVER, BC, May 20, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”), a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the appointment of Dr. Joel Raskin as Chief Medical Officer. A trusted and respected leader in the neuroscience community, Dr. Raskin possesses two decades of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization.

As Chief Medical Officer with MINDCURE, Dr. Raskin will play a lead role in the company’s drug research, development, and commercialization approach. He has additional expertise around several priority indications identified by MINDCURE, including migraines, depression, and anxiety. Dr. Raskin earned his Medical degree and his FRCPC Psychiatry from the University of Toronto. Dr. Raskin had a 20-year career holding various neuroscience leadership positions at pharmaceutical company Eli Lilly & Co. He currently serves on the Alzheimer’s Drug Development Foundation Scientific Review Committee and the Weston Family Foundation Brain Institute Scientific Advisory Committee.

“I am thrilled today to be joining the team at MINDCURE as Chief Medical Officer,” said Dr. Joel Raskin. “In my 35 years of pharmaceutical and psychiatric experience, I have seen firsthand the shortcomings of existing treatments and drugs. It is an exciting opportunity ahead for MINDCURE, and this industry in general, to find more effective and safer treatments for psychiatric and neurological diseases.”

“As we continue to build our world-class executive team, we are extremely pleased to welcome Dr. Raskin to MINDCURE,” said Kelsey Ramsden, President and CEO of MINDCURE. “Dr. Raskin is a recognized leader in the area of neuropsychiatry research and treatment, and he will play a key role in advancing our mission to improve mental health in our communities through scientific psychedelic research and drug development.”

About Dr. Joel Raskin

Dr. Joel Raskin was a community psychiatrist and academic with 20 years of international pharmaceutical experience in neuroscience drug development, lifecycle preparation, launch, and commercialization. He earned his medical degree and FRCPC, Psychiatry at the University of Toronto. He is currently on the Alzheimer’s Drug Development Foundation Scientific Review Committee and the Weston Family Foundation Brain Institute Scientific Advisory Committee.

Dr. Raskin is a member of the Canadian Medical Association, Ontario Medical Association, and Royal College of Physicians and Surgeons. As an active member of the academic and life sciences community, Dr. Raskin, until recently, held an adjunct staff appointment with the University of Toronto Department of Psychiatry.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain information presented in this news release may constitute “forward-looking information” within the meaning of applicable securities laws regarding MINDCURE and its business.  Forward-looking information inherently entails known and unknown risks and uncertainties about the future and actual results, performance or achievements contemplated by forward-looking statements made may be materially different from the results anticipated or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: the company’s ability to conduct an effective drug research, development, and commercialization program and advance its mission to improve mental health with the addition of Dr. Raskin to the team.

Forward-looking information is based on a number of key expectations and assumptions made by management of MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and Mind Cure’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect Mind Cure’s business; there will be a demand for Mind Cure’s products in the future; no unanticipated expenses or costs arise; Mind Cure will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; that the addition of Dr. Raskin will help Mind Cure achieve its business goals; and that Mind Cure will be able to operate its business as planned.

Although Mind Cure has attempted to identify important factors that could cause actual results, performance or achievements to differ materially from those described in forward-looking information presented, there may be other factors that cause results, performance or achievements to differ from those anticipated, estimated or intended. Accordingly, readers should not place undue reliance on any forward-looking statements as no forward-looking information can be guaranteed.

Except as required by applicable securities laws, forward-looking statements speak only as of the date on which they are made and Mind Cure does not undertake any obligation to publicly update or revise any forward-looking information, whether as a result of new information, future events, or otherwise.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com, 1-888-593-8995; Jonathan L. Robinson, CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

MINDCURE Appoints Dr. John Brownstein, the Chief Innovation Officer at Boston Children’s Hospital, as Company Advisor

Dr. Brownstein, an esteemed epidemiologist, researcher at Boston Children’s Hospital and professor at Harvard Medical School, will assist on MINDCURE’s digital technology, data optimization and patient data security within iSTRYM, its psychedelic digital therapeutics platform.

VANCOUVER, BC, May 19, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the addition of Dr. John Brownstein as Advisor to the Company. Dr. Brownstein, the Chief Innovation Officer at Boston Children’s Hospital and a Professor of Medicine at the Harvard Medical School, is world-renowned for his pioneering approach to data management and technology within health care. The HealthMap system he founded was the first electronic disease surveillance program to issue an alert for COVID-19 in late December of 2019. Dr. Brownstein and his team also run Vaccine Finder, a platform to help people more easily find clinics and pharmacies that offer COVID-19 vaccinations.

In his role as Advisor, Dr. Brownstein will help to inform the development and deployment of iSTRYM, MINDCURE’s psychedelics digital therapeutics platform, and related technologies. Dr. Brownstein is also published extensively on issues of patient privacy, and his expertise will enable MINDCURE to best optimize the translation and utilization of patient data collected through iSTRYM, with the intended goal to uncover optimal protocols and treatment methods.

“I am thrilled to be joining the MINDCURE team today as an Advisor. With iSTRYM, MINDCURE is creating a platform to improve mental health treatments across the globe through better understanding patient and research data within psychedelics, with the hope of unlocking tremendous value for researchers, therapists, and ultimately patients in need,” said Dr. John Brownstein. “I believe that my experience of building technology to better collect, understand, and unlock insights from large patient data sets across the globe will enable MINDCURE to build iSTRYM into a valuable resource for the entire psychedelics industry.”

“Dr. Brownstein understands the opportunity we have to improve efficacy in the medical field by putting real-world data to use,” said Kelsey Ramsden, President & CEO, MINDCURE. “It is early days for this in the psychedelics industry, but we see an amazing opportunity for iSTRYM to become the go-to platform of choice for researchers, therapists and patients around the world. We are honoured that Dr. Brownstein will be joining us as an Advisor. His credentials, experience, and track record speak for themselves and his contributions to the global medical community are unrivaled.”

About Dr. John Brownstein

Dr. Brownstein is the Chief Innovation Officer of Boston Children’s Hospital and Professor of Biomedical Informatics at Harvard Medical School. He also directs the Computational Epidemiology Lab and the Innovation and Digital Health Accelerator both at Boston Children’s. He was trained as an epidemiologist at Yale University. Overall, his work aims to have translation impact on the surveillance, control and prevention of disease. He has been at the forefront of the development and application of data mining and citizen science to public health. His efforts are in use by millions each year including the CDC, WHO, DHS, DOD, HHS, and EU, and has been recognized by the National Library of Congress and the Smithsonian. In addition to research achievements, this translational impact comes from playing an advisory role to numerous agencies on real-time public health surveillance including HHS, DHS, CDC, IOM, WHO and the White House.

He was awarded the Presidential Early Career Award for Scientists and Engineers, the highest honor bestowed by the United States government to outstanding scientists and the Lagrange Prize for international achievements in complexity sciences. Dr. Brownstein is co-founder of digital health companies Epidemico and Circulation. He has authored over 250 peer-reviewed articles on epidemiology and public health. This work has been reported on widely including pieces in the New England Journal of Medicine, Science, Nature, New York Times, The Wall Street Journal, CNN, National Public Radio and the BBC.

The Company also announces it has granted a total of 360,000 stock options to certain employees or consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable: 10,000 at a price of $0.60 per share, 250,000 at a price of $0.38 per share and 100,000 at a price of $0.32 per share and are subject to the terms of the Plan.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Dr. Brownstein assisting MINDCURE on its digital technology, data optimization and patient security within iSTRYM; MINDCURE optimizing the translation and utilization of patient data collected through iSTRYM; and MINDCURE building iSTRYM into a valuable resource for the entire psychedelics industry.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Dr. Brownstein assisting MINDCURE on its digital technology, data optimization and patient security within iSTRYM; MINDCURE optimizing the translation and utilization of patient data collected through iSTRYM; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Dr. Brownstein may not assist MINDCURE on its digital technology, data optimization and patient security within iSTRYM; MINDCURE may not optimize the translation and utilization of patient data collected through iSTRYM; and MINDCURE building iSTRYM into a valuable resource for the entire psychedelics industry.; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson, CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM’s Market Launch, Delivering Mental Wealth

MINDCURE is well-positioned to capitalize on its near-term revenue strategy, complete beta testing and launch of digital therapeutic tool iSTRYM and further its research into psychedelics

VANCOUVER, BC, April 29, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to share updates today on its financial position, near-term revenue strategy, timeline for iSTRYM’s market launch, as well as its research plans and products for both psychedelics and nootropics designed to accompany the use of psychedelic medicines.

Financial Update

With MINDCURE’s most recent equity raise of $23 million this past February, the Company believes it is well-positioned financially with a clear path to near-term revenues through its technology platform and nootropics product line. MINDCURE also announced last week the hiring of an experienced M&A and capital markets financial leader, Michael Wolfe, as the Company’s new Chief Financial Officer. “We are well-positioned financially to capitalize on opportunities in the short term while concurrently doubling down on our key strategic focuses which we have been sharing with the market over the past several months,” said Kelsey Ramsden, MINDCURE President and CEO.

Near-term revenue generation is a key part of MINDCURE’s financial strategy. It expects a commercial rollout of its digital therapeutics platform, iSTRYM, by Q1 2022, and currently sells its nootropic supplements through MINDCURE Wellness (www.mindcurewellness.com). The Company is also developing proprietary formulations for before (pre) and after (post) psychedelic-assisted psychotherapy, to help patients prepare for and integrate from their sessions.

“MINDCURE recognizes the value of blue sky opportunities in drug development and while we pursue the establishment of a clearly differentiated research program from other psychedelic companies, leading with synthesizing ibogaine, we believe strongly that bottom line fundamentals are essential,” said Mrs. Ramsden. “And that is why we are developing horizons of realizable revenue through a planned global SaaS rollout with iSTRYM anticipated to become a platform backbone of the psychedelic-assisted psychotherapy industry with our AI driven technology.”

iSTRYM

With a series of recent partnership announcements with Speak Ai Inc. (“Speak Ai”), LUCID Inc. (“LUCID”), and SOMA Breath Inc. (“SOMA Breath”), MINDCURE is committed to building iSTRYM into the go-to resource that therapists and patients will turn to for science-backed, personalized psychedelic and non-psychedelic mental health care at scale. Speak Ai is developing custom integrations of its data collection software to enable iSTRYM to marry sentiment with biometric data, location, weather, and a variety of other variables to help optimize its integration protocols and provide individuals with quantified care at scale globally, across a variety of psychedelic medicine protocols. LUCID is designing custom AI-based music experiences within iSTRYM to enhance the effectiveness of psychedelic treatments, and SOMA Breath is building a custom breathwork track in addition to licensing its existing breathwork platform, which will enable therapists to design more effective sessions and also increase the likelihood of an effective post-session integration for patients.

The beta version of the iSTRYM is scheduled to launch this August, and the development is both on track and on budget. “We are both pushing really fast and being very thoughtful with iSTRYM’s build-out,” continued Mrs. Ramsden. “We want to ensure that this platform will effectively serve the needs of the market, for both therapists and patients, and researchers as well. This is why we have selected best-in-class partners and integrations across the spectrum of mental health treatments, and brought in people such as Ty Tashiro and Daniel Herrera to the team.” Mr. Tashiro, MINDCURE’s Senior Translational and Psychometric Architect, is an expert in psychometrics and is guiding the development of client assessments, as well as specific items and scales for proprietary use within iSTRYM to ensure that therapists have the tools they need to be successful.

Additionally, with its investment in ATMA Journey Centers Inc. (“ATMA“), MINDCURE believes it has a direct go-to-market strategy to get iSTRYM into the hands of therapists and patients. And beyond ATMA, Mr. Herrera is leading strategic partnerships that are planned to leverage iSTRYM with additional mental health partners across the psychedelics and health care value chain, with the intention of driving platform engagement of iSTRYM among researchers, therapists and patients.

Research & Science

Led by Dr. Ryan Hartwell, Dr. Dan Engle and a team of world-renowned researchers and scientists at the forefront of psychedelics, MINDCURE’s science arm is focused on the synthetic production of pharmaceutical grade ibogaine, supporting Dr. Engle’s work as the Primary Investigator into treating traumatic brain injuries (TBIs) through psychedelic-assisted psychotherapies, and leveraging PsyCollage, the Company’s first-generation bioinformatics platform, intended to drive more meaningful clinical work and research programs.

“PsyCollage provides the data and tools necessary for our scientific team to make informed decisions, and for us as a Company to allocate our capital and resources into the most meaningful opportunities and best possible outcomes,” said Mrs. Ramsden. “Our research starts with identifying opportunities to improve how the world treats mental health issues. Then, we develop solutions for commercialization.”

As mentioned above, MINDCURE is also developing proprietary pre and post-therapy session nootropics to add to its existing product line. “We view both our existing nootropics and adaptogen products as well as these coming formulations as an important part of our near-term revenue generation strategy,” continued Mrs. Ramsden. “While the benefits of functional mushrooms are well known to many, we see a clear opportunity to  develop supplement products aimed specifically at supporting the psychedelic experience.”

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE being well-positioned to capitalize on its near-term revenue strategy; MINDCURE developing proprietary formulations for pre and post psychedelic-assisted psychotherapy; Speak Ai developing custom integrations of its software for iSTRYM; LUCID designing custom AI-based music experiences within iSTRYM; SOMA Breath building a custom breathwork track and licensing its existing breathwork program; the MVP of iSTRYM launching in August; and MINDCURE producing synthetic ibogaine.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; MINDCURE developing proprietary formulations for pre and post psychedelic-assisted psychotherapy; Speak Ai developing custom integrations of its software for iSTRYM; LUCID designing custom AI-based music experiences within iSTRYM; SOMA Breath building a custom breathwork track and licensing its existing breathwork program; the MVP of iSTRYM launching in August; and MINDCURE producing synthetic ibogaine; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; MINDCURE may not develop proprietary formulations for pre and post psychedelic-assisted psychotherapy; Speak Ai may not develop custom integrations of its software for iSTRYM; LUCID may not design custom AI-based music experiences within iSTRYM; SOMA Breath may not build a custom breathwork track and licensing its existing breathwork program; the MVP of iSTRYM may not launch in August; MINDCURE may not produce synthetic ibogaine; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

MINDCURE Announces Partnership with SOMA Breath Inc. to License its Breathwork Program and Develop Custom Breathwork for Psychedelic-Assisted Psychotherapies within iSTRYM

Breathwork has shown promise at both replicating the experience of psychedelics and helping patients to integrate psychedelic-assisted psychotherapy into their lives

VANCOUVER, BC, April 27, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership and licensing agreement with SOMA Breath Inc. (“SOMA Breath”). The term breathwork refers to breathing exercise techniques that manipulate the depth and rate of breath, and SOMA Breath is a global school that combines ancient breathwork techniques based on pranayama with modern science.

MINDCURE will license SOMA Breath’s 21-day mental health-designed breathwork program and will also build a custom breathwork track targeted towards psychedelic-assisted psychotherapies, both within iSTRYM, its psychedelics digital therapeutics platform. SOMA’s breathwork programs have been proven to help patients manage stress and reduce anxiety, and have been shown to produce brainwave activity in patients comparable to the effect of psychedelics.1 MINDCURE intends to create opportunities for therapists and patients to utilize SOMA Breath breathwork programs to foster psychedelic-like experiences without the need for psychedelics themselves, while also enhancing the effectiveness of post-session integration for psychedelic-assisted psychotherapies.

With existing partnerships to develop technology integrations and custom services in place with Speak Ai, LUCID and now Soma Breath, MINDCURE is building iSTRYM into the go-to resource that therapists and patients will turn to for science-backed, personalized mental health support at scale. The Company anticipates a late July release of the beta version of the iSTRYM application and platform.

“We think it is important to give individuals options in building their mental wealth, both when they are engaged in psychedelic-assisted psychotherapy as well as when they are not and are simply seeking better mental performance,” said Kelsey Ramsden, MINDCURE President and CEO. “SOMA Breath’s validated techniques and protocols will enable therapists to design psychedelic-like treatments without the need for actual psychedelics, and also to enhance the effectiveness of post-session integration, which is a key area of focus for us within iSTRYM.”

“At SOMA Breath, we have seen firsthand the transformational power of breathwork, and are eager to bring our scientifically-validated program into iSTRYM for therapists and patients around the world, and to work alongside MINDCURE to further the connection between breathwork and psychedelic-like experiences,” said Niraj Naik, the Founder and CEO of SOMA Breath. “We believe that the breath is the key to unlocking peak performance and also can serve an important role in the treatment of many debilitating mental health illnesses, and it can be accessed anywhere, by anyone, at any time.”

Dr. Jeff Tarrant, the founder of the Neuro Meditation Institute in Eugene, Oregon,2 studied the impact of SOMA Breath breathwork techniques on the brain, and then compared the results with available research on traditional psychedelics. The results showed that breathwork meditation is able to produce similar experiences to those of traditional psychedelics.3

_______________________

1

https://www.counselling-directory.org.uk/blog/2020/10/23/how-breathwork-can-help-to-manage-stress-and-anxiety

2

https://www.neuromeditationinstitute.com/about-nmi

3

https://www.somabreath.com/wp-content/uploads/2019/10/Can-Breathing-Be-a-Psychedelic-1.pdf

About SOMA Breath Inc.

SOMA Breath’s overall mission is to empower people with knowledge, tools, and techniques to make positive and lasting change in their lives. SOMA Breath techniques have the power to transform someone even down to a cellular level. SOMA Breath, considered as a whole, with its range of possible uses and applications, is a framework for total life transformation.

SOMA Breath is a complete holistic system of Pranayama techniques, which can be arranged into different sequences depending on the type of workshop you are attending as well as tailored to your specific needs. There is no one size fits all, and we take into account the fact that everyone is different and requires different breathing techniques depending on their needs. SOMA Therapeutic Breathwork techniques are the core Pranayama techniques that have the most scientific evidence to support their function.

About iSTRYM™ Digital Therapeutics

iSTRYM is a first-of-its-kind software application that optimizes the healing journey for both patients and clinicians — before, during, and after therapy sessions. iSTRYM enhances therapy by bringing together a variety of healing solutions, such as convenient user dashboards, integrative music, guided breathwork, intelligent language processing, secure data analysis, and more.

Offering real-world data in real-time, iSTRYM enables clinicians and their clients access to personalized technology that provides AI-driven data insights for improved clinical outcomes. From mindful integrative content to a repository of world-class treatment plans, iSTRYM provides the best in psychedelic therapy software. iSTRYM drives personalized, quantified and best-in-class outcomes in psychedelic therapy, making Mental Wealth™ accessible.

The Company also announces it has granted a total of 50,000 stock options to certain employees pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.60 per share and subject to the terms of the Plan.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: SOMA Breath developing custom breathwork for MINDCURE; MINDCURE licensing SOMA Breath’s existing 21-day mental health designed breathwork program; iSTRYM will meet its target beta release of late July 2021; SOMA Breath’s programs enabling therapists to design psychedelic-like treatments without the need for actual psychedelics; and SOMA Breath’s programs helping patients to integrate post-therapy session.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; SOMA Breath will develop a custom breathwork track for iSTRYM; iSTRYM’s beta version will be ready by late July, 2021; breathwork will help patients to manage stress and reduce anxiety; MINDCURE will create opportunities for therapists and patients to utilize breathwork programs to foster psychedelic-like experiences without the need for psychedelics; and that breathwork will enhance post-session integration for patients; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; SOMA Breath may not develop a custom breathwork track for iSTRYM; iSTRYM’s beta version may not be ready by late July, 2021; breathwork may not help patients to manage stress and reduce anxiety; MINDCURE may not create opportunities for therapists and patients to utilize breathwork programs to foster psychedelic-like experiences without the need for psychedelics; breathwork may not enhance post-session integration for patients; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com, 1-888-593-8995; Jonathan L. Robinson, CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

MINDCURE Announces Experienced Finance Executive Michael Wolfe as CFO and appoints Larissa Chaikowsky to its Board of Directors

Mr. Wolfe has extensive capital markets and debt and equity financing experience; Ms. Chaikowsky, the COO at BMO Wealth Management, has significant expertise in corporate governance, human resources and operational risk management

VANCOUVER, BC, April 22, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased today to announce the hiring of Michael Wolfe as the company’s new Chief Financial Officer. Mr. Wolfe possesses over 30 years of financial leadership and private equity experience and most recently served as the CFO at Baylin Technologies, a TSX-listed company in the wireless communications industry. In an additional appointment also announced today, MINDCURE has named Larissa Chaikowsky to its Board of Directors. Stephen Inouye will be stepping down from his position on the Board, as well as from the CFO role for personal reasons to make way for Ms. Chaikowsky and Mr. Wolfe, respectively.

Mr. Wolfe’s experience with raising capital through markets, financial institutions, and investment banks will be important as MINDCURE continues to build its team, its technology, and its leadership position within the psychedelics industry.  He has a successful track record in mergers and acquisitions, growth financings and recapitalizations in diverse industries such as cable, manufacturing and global logistics. “I am honoured to be joining MINDCURE at this exciting stage of company growth. Mrs. Ramsden is an impressive CEO and so is the team she is building around her,” said Michael Wolfe, MINDCURE CFO. “In addition to having worked with established mid-market companies, I was the CFO of an early-stage health app and am excited by the potential of iSTRYM to serve a large global market in need.”

“I would first like to thank Stephen Inouye for his instrumental role in our first chapter at MINDCURE,” said MINDCURE CEO and President Kelsey Ramsden. “We continue to build a world-class executive team over the past months, with a particular focus on what we intend to do better than anybody else with our digital therapeutics strategy driving near-term revenue and pre-clinical research underway. Mr. Wolfe has a strong background in the capital markets, and his particular financial expertise with regards to capital raising, acquisitions and the public markets are of immense value to MINDCURE.”

Ms. Chaikowsky currently serves as the COO of US Wealth Management at the BMO Financial Group and has served a variety of leadership roles at the company through her 15+ year career there. “I am very excited to join the MINDCURE Board of Directors. I am passionate about innovation, and particularly around mental health care through psychedelics,” said Larissa Chaikowsky. “Mrs. Ramsden has assembled an impressive Board and I look forward to bringing my expertise within corporate governance, operational risk management, and human resources to MINDCURE as its rapid growth continues.”

“Ms. Chaikowsky is a premier executive with a stellar track record of success. She is a no-nonsense and passionate leader with very relevant experience for us in regulated industries, particularly in the United States,” continued Mrs. Ramsden. “We will lean on her significantly for her expertise with internal human resource structure as well as with her network and connections in banking and the capital markets.”

About Michael Wolfe:

Mr. Wolfe has over 30 years’ experience in finance, accounting. private equity and business valuation. He was most recently the Chief Financial Officer of Baylin Technologies Inc., a TSX listed company in the wireless communications industry.  Prior to joining Baylin, Michael was the Chief Financial Officer of several mid-market Canadian companies including Masstech Group Inc., a software company in the broadcast industry. As a General Partner at VenGrowth Capital Partners Inc., Michael had a successful track record in acquisitions, management buyouts, growth financings and recapitalizations in diverse industries such as cable, broadcast, manufacturing, insurance, oil field services and global logistics.

Mr. Wolfe has also served as a director for several private and public companies, including as a member of audit and other independent committees. He earned a CPA, CA designation, a Chartered Business Valuator designation, an MBA from McMaster University, and a BA (Business and Economics) from the University of Western Ontario.

About Larissa Chaikowsky:

Larissa Chaikowsky is the Chief Operating Officer for the U.S. Wealth Management business at BMO. She leads the National Office Teams and oversees the planning, development and implementation of product and service strategies for BMO Financial Group’s U.S. Wealth businesses. Prior to this role, Larissa was the U.S. Chief Human Resources Officer for BMO Financial Group. She oversaw the strategic and operational governance processes of the U.S. HR organization. She executed enterprise HR overseeing and coordinating human resources related matters as they pertain to: U.S. regulatory agencies, and U.S. mergers and acquisitions. Larissa had a leadership role with the Human Resources Committee of the BMO Financial Corp board of Directors and the Benefits Investment Committee. She also chaired the U.S. Compensation Oversight Committee and the U.S. Benefits Administration Committee.

During her fifteen-year tenure with BMO, Larissa has held several senior positions that have played a role in helping redefine the BMO brand and improving the business practices of Technology and Operations, Human Resources and Corporate Strategy. Larissa received her Bachelor of International Business and Relations from the Sprott School of Business and holds an MBA from the Richard Ivey School of Business.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE’s digital therapeutics strategy driving near-term revenues; Mr. Wolfe’s strong background and expertise being immense value to MINDCURE; Ms. Chaikowsky bringing her expertise to MINDCURE as rapid growth continues; and MINDCURE leaning on Ms. Chaikowsky significantly for her expertise with human resources, network and connections.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; MINDCURE’s digital therapeutics strategy will drive near-term revenues; Mr. Wolfe will provide immense value to MINDCURE; Ms. Chaikowsky will bring her expertise to MINDCURE as rapid growth continues; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; MINDCURE’s digital therapeutics strategy may not drive near-term revenues; Mr. Wolfe may not provide immense value to MINDCURE; Ms. Chaikowsky may not bring her expertise to MINDCURE as rapid growth continues;; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson, CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

‍

Posted on

MINDCURE Partners its iSTRYM Technology with LUCID to Discover and Create Proprietary Music Experiences for Use During Psychedelic-Assisted Therapy Sessions

LUCID’s technology platform unites music, AI and research in neuroscience to create personalized digital music therapy managed in real-time by therapists based on patient feedback

VANCOUVER, BC, April 21, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce a partnership with LUCID Inc. (“LUCID”). LUCID’s mission is to help people optimize their mental wellness through music, and they will be designing custom psychedelic music experiences for iSTRYM.

After announcing its data partnership with Speak Ai last week, MINDCURE continues to integrate world-class technologies into and create proprietary experiences within iSTRYM, its psychedelics digital therapeutics platform. LUCID’s platform is a key differentiator for iSTRYM as therapists and patients seek out scientifically validated tools to enhance the effectiveness of psychedelic-assisted therapies. It will enable the therapist to alter the music within a therapy session based on real-time feedback and data collected from the patient, all within iSTRYM.

“We look forward to working with MINDCURE’s team and bringing our expertise to psychedelic-assisted therapies,” said Zach McMahon, LUCID CEO and Co-Founder. “Our team will be researching and taking into consideration the therapeutic targets and mechanisms of action associated with each psychedelic while leveraging our machine learning systems to optimize the music experiences in iSTRYM for personalization and efficacy.”

Music has been shown to be effective as a stress and anxiety management tool and also has shown efficacy for diverse outcomes, including chronic and acute pain.1 Listening to music evokes a wide range of emotions,2 and because of this, music listening has been a component of several psychological interventions in the area of anxiety and depression, such as post-traumatic stress disorder.3,4 With this integration, therapists will have access to music designed for psychedelic-assisted therapies and specific psychedelic compounds that is changing in real-time based on patient feedback, AI and collected data to deepen or alter the experience.

__________________________

1 Choi et al.. 2018; Vaajoki et al., 2010; Shabanloei et al., 2010; Good et al., 2005; Smyth et al., 2018; Chai et al., 2020;
Jangsirikul et al., 2017

2 Bandelow, B., & Michaelis, S. (2015). Epidemiology of anxiety disorders in the 21st century. Dialogues in Clinical
Neuroscience, 17(3), 327–335.

3 Bensimon, M., Amir, D., & Wolf, Y. (2012). A pendulum between trauma and life: Group music therapy with post-
traumatized soldiers. The Arts in Psychotherapy, 39, 223–233. doi:10.1016/j. aip.2012.03.005

4 Panteleeva, Y., Ceschi, G., Glowinski, D., Courvoisier, D. S., & Grandjean, D. (2018). Music for anxiety? Meta-analysis of
anxiety reduction in non-clinical samples. Psychology of Music, 46(4), 473–487.

“We are building first-of-its-kind functionality by pairing AI-driven music scapes with a therapist’s art of directing the experience for patients in psychedelic-assisted therapy sessions,” said Kelsey Ramsden, MINDCURE President and CEO. “Integrating LUCID will further enhance iSTRYM’s capabilities and its potential as the validated backbone of the roll-out of psychedelic therapy and trusted wingman for therapists and patients who want a digital therapeutic partner that allows for quantified medicine with personalization at scale.”

“Music interventions have well-indicated positive effects on anxiety and depression, and are frequently used alongside psychedelic therapies. We recently concluded a randomized controlled trial of LUCID’s personalized music technology and found it to be more effective than comparator technologies in alleviating symptoms of anxiety in adults diagnosed with moderate trait anxiety. We plan to continue building this body of evidence in diverse use-cases, including as an adjunct to psychedelic therapy,” said Dr. Frank Russo, Professor of Psychology and Director of the SMART Lab at Ryerson University.

LUCID’s core technology is based on the use of quantitative measurement of mood and physiological state, coupled with robust personalization techniques made possible by machine learning, to optimize music interventions for specific cognitive outcomes. Using psychometric and biometric measurement to determine the user’s current mental state and machine learning agents, LUCID systems adaptively predict the optimal musical sequence to help an individual reach their desired state.

These tools are further leveraged to intelligently compose, produce, and remix music with the highest possible therapeutic potential for precise outcomes. In addition to the music, LUCID employs a novel method to seamlessly integrate auditory beat stimulation (including binaural beats) within the fabric of the music for additional benefit.

About LUCID Inc. (LUCID):

LUCID‘s mission is to transform the mental health industry by unlocking the potential of music therapy through innovative AI technology. LUCID emphasizes non-invasive and accessible tools to help people with their mental health, by providing evidence-based and scientifically-validated personalized music therapies based on real-time mood assessment. With patented technology and a clinical research pipeline, LUCID is committed to scientifically validating music as medicine.

LUCID’s partners and collaborators include Mitacs, the Ontario Brain Institute, Ontario Centres of Excellence, Next Canada, MaRS, and Ryerson University. LUCID’s advisors include Dr. Rébecca Kleinberger from MIT Media Lab,  CAMH’s Chief of General and Health Systems Psychiatry Dr. Farooq Naeem, Ryerson SMART Lab’s Dr. Frank Russo, and Dr. Sageev Oore of Dalhousie’s Vector Institute of AI.

The Company also announces it has granted a total of 610,000 stock options to certain employees or consultants pursuant to the terms the Company’s incentive stock option plan (“Plan”). The stock options are exercisable at a price of $0.60 per share and subject to the terms of the Plan.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: LUCID creating proprietary music experiences for MINDCURE; music enhancing a patient’s experience during psychedelic-assisted therapy sessions; and that this integration further enhancing iSTRYM’s capabilities and its potential as the validated backbone of psychedelic therapy.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; LUCID will develop custom psychedelic music experiences for MINDCURE; music will help therapists using iSTRYM as well as patients during psychedelic-assisted therapy sessions; iSTRYM will become the validated backbone of psychedelic therapy; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; LUCID may not develop custom psychedelic music experiences for MINDCURE; music may not help therapists using iSTRYM as well as patients during psychedelic-assisted therapy sessions; iSTRYM may not become the validated backbone of psychedelic therapy; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations, investors@mindcure.com, 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

‍

Posted on

MINDCURE Announces The Addition of Daniel Herrera, A Pharmaceutical Industry Executive With Specific Experience in Medical Psychoactive Segment

Mr. Herrera, Who Will Join The Company As Its Vice President Of Growth And Strategic Partnerships, Has 15+ Years Of Global Life Sciences Experience And Will Help To Drive MINDCURE’s Commercial Focus And Strategic Partnerships

VANCOUVER, BC, April 14, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce the addition of Daniel Herrera as Vice President, Growth and Strategic Partnerships. Mr. Herrera joins the company with extensive experience in the life sciences industry, where he has led teams and divisions at high-growth start-ups as well as large multinational pharmaceutical companies.

Most recently, he led Corporate Development at Medcolcanna, a Canadian integrated medical cannabis company that is situated in Colombia, as their Chief Corporate Development Officer, where he managed global partnerships within the highly regulated medical cannabis industry. During his tenure there, Mr. Herrera gained specific experience in the psychoactive medical cannabis segment as he helped lead the company’s efforts to have the Colombian Government grant the company the authorization to manufacture psychoactive medical cannabis derivatives.

Prior to joining Medcolcanna, Mr. Herrera was with CannTrust Holdings Inc., where he was Director of Global Strategy and Business Development as well as leading the Global Partnerships and Investments group, where he advised on several M&A and sales transactions in Denmark, Germany, Australia and the US, including acquisition and licensing of technologies related to the cannabis and biopharmaceutical sectors. He has over 15 years’ experience in the pharmaceutical industry serving in various commercial and strategic roles at Eli Lilly and Company.

“MINDCURE’s core mission to identify, develop and provide solutions to the healthcare community that ease suffering, increase productivity, and enhance mental health is what really attracted me to this opportunity, ” said Daniel Herrera, MINDCURE Vice President, Growth and Strategic Partnerships. “Having worked over many years with key stakeholders in hospitals, governments and with payers globally to establish new treatment paradigms and improved patient access to novel medicines, I understand the importance of trust and collaboration within partnerships and stakeholder relations in health care. As MINDCURE further establishes itself as a life sciences leader in this nascent space, I hope to help accelerate its growth with the experience gained from the highly regulated pharmaceutical and cannabis industries.”

In this new position at MINDCURE, Daniel will focus on establishing strategic partnerships that help with the Company’s sales efforts, leveraging MINDCURE’s technology and research expertise with mental health partners across the psychedelics and health care value chain. He will also spearhead the company’s mission to be a premier service provider for therapist deployment of psychedelic care and develop industry partnerships that drive platform engagement of iSTRYM.

“Daniel’s track record of success makes him a great addition to our team as we drive penetration of our technology product and develop long term relationships targeting our research outcomes,” said Kelsey Ramsden, MINDCURE President and CEO. “He has the life sciences industry credibility from his experience working with doctors, medical professionals, and governments around the world. He is also the right person to help us further build out MINDCURE’s commercial team and help quicken the Company’s continued growth via Joint Ventures, Partnerships and M&A transactions.”

About Daniel Herrera:

Daniel Herrera is a pharmaceutical executive with extensive experience in large and startup pharmaceutical organizations and a proven track record in translating business strategy into actionable goals for growth, and profitability in highly regulated industries. His experience ranges from sales and marketing management to medical affairs, product development and product licensing, to negotiations with public and private payers, GPOs, and pharmacy buyers, to operations and strategic business development, and strategic partnerships resulting in high-value M&A transactions.

Daniel is a graduate of McGill University, the University of Montreal and earned an MBA from the John Molson School of Business at Concordia University.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Mr. Herrera helping to drive MINDCURE’s commercial focus and strategic partnerships; Mr. Herrera’s experience in the pharmaceutical industry to help accelerate MINDCURE’s growth; Mr. Herrera establishing meaningful partnerships for MINDCURE’s strategic sales efforts; Mr. Herrera spearheading MINDCURE’s mission to be the premier service provider for therapist deployment of psychedelic care; Mr. Herrera developing industry partnerships that drive platform engagement; and Mr. Herrera being the right person to help MINDCURE further build out its commercial team.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Mr. Herrera will help MINDCURE to accelerate its strategic sales efforts; Mr. Herrera will develop industry partnerships to drive platform engagement; Mr. Herrera will be the right person to help MINDCURE further build out its commercial team; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Mr. Herrera may not help MINDCURE to accelerate its strategic sales efforts; Mr. Herrera may not develop industry partnerships to drive platform engagement; Mr. Herrera may not be the right person to help MINDCURE further build out its commercial team; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

MINDCURE Announces Partnership with Speak Ai to Enhance iSTRYM, the Company’s Psychedelic Digital Therapeutics Technology Platform

Utilizing Speak Ai’s technology, iSTRYM will provide Ai-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy

VANCOUVER, BC, April 13, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce that it has entered into a partnership with Speak Ai Inc. (“Speak Ai”). The Canadian-based technology company helps individuals and organizations analyze media, language, and metadata to automatically generate valuable insights through machine learning. MINDCURE will be integrating the platform’s capabilities into iSTRYM, and will also work with Speak Ai to develop proprietary, technology-based mental health solutions.

By combining audio, video, and text analysis with metadata in a single platform, Speak Ai has developed a comprehensive solution for generating personalized insights to improve research and personal wellbeing. Their technology has been honed over several years of development, research, and experience, and the organization has built a strong reputation within the psychedelic community.

“We are proud to partner with MINDCURE today to help build iSTRYM into a powerful solution for therapists and patients around the world,” said Tyler Bryden, Speak Ai Founder. “I have had the privilege to witness the potential of psychedelic-assisted therapies in my own life and in the lives of amazing people around me who are healing from anxiety, depression, PTSD, traumatic brain injuries, and more.”

This partnership will result in driving data for iSTRYM, taking unstructured data, and creating structure and metrics for the platform integration. Natural language processing with machine learning allows MINDCURE to drive insights for the therapist and patient. This information is often difficult to capture using traditional methods during the course of therapy.

“By developing solutions with empathy, we can improve the level of care to help people avoid, navigate through and recover from crises. We share the belief with MINDCURE that technology can play a major role in enabling these potentially life-changing and individual therapies to succeed at scale,” continued Bryden.

“We are excited to work with Tyler and the team at Speak Ai because of their intimate knowledge of the value of technology in the therapeutic and integration process within psychedelics and the traditional therapeutic model,” said MINDCURE CEO and President Kelsey Ramsden. “We will be building custom integrations with Speak Ai for the iSTRYM platform that allow us to marry sentiment with biometric data, location, weather, and a variety of other variables to help optimize our integration protocols and provide individuals with quantified care at scale globally, all with the stated goal of advancing Mental Wealth, rooted in data.”

About Speak Ai Inc.

Speak Ai is a technology company harnessing the power of AI to help individuals and organizations transform their media into incredible assets for growth. By combining audio, video, and text analysis with metadata in a single platform, the Speak Ai team has developed a comprehensive solution for generating personalized insights that improves research and wellbeing.

Speak Ai works with well-established organizations like the London Health Sciences Centre and Ryerson University to improve recording systems, create transcripts, analyze audio and video quicker and less expensively, and provide an interactive media interface to easily navigate through long recordings. One of the researchers from LHSC said: “This is a complete paradigm shift for how we do research.”

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: Speak Ai developing proprietary mental health technology-based solutions for MINDCURE; iSTRYM becoming a must-have solution for therapists and patients around the world; this partnership driving data for iSTRYM; MINDCURE significantly improving the level of care, help people avoid and recover from crises and enable them to reach their fullest potential; and MINDCURE advancing Mental Wealth, rooted in data.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; Speak Ai will develop proprietary mental health technology-based solutions for MINDCURE; iSTRYM will become a must-have solution for therapists and patients around the world; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments; Speak Ai may not develop proprietary mental health technology-based solutions for MINDCURE; iSTRYM may not become a must-have solution for therapists and patients around the world; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Connect: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

Posted on

MINDCURE Announces Additional Equity Investment in ATMA, The First Government Approved Psychedelic Journey Centers In Canada; MCUR President and CEO, Kelsey Ramsden Named to ATMA Board of Directors

ATMA Was The First Private Sector Service Provider In Canada Conducting Legal Psychedelic-Assisted Therapy For A Palliative Care Patient Under The Approval Of Health Canada’s Section 56(1) Exemption

VANCOUVER, BC, April 8, 2021 /CNW/ – Mind Cure Health Inc. (CSE: MCUR) (OTCQB: MCURF) (FRA: 6MH) (“MINDCURE” or the “Company”) a leader in advanced proprietary technology for psychedelic therapy, is pleased to announce a further strategic equity investment in ATMA Journey Centers Inc. (“ATMA“). This follow-on investment enables MINDCURE to retain its 13% ownership of ATMA, in accordance with the terms of the letter of intent (the “LOI“) announced on January 12, 2021. Additionally, MINDCURE President and CEO Kelsey Ramsden will be joining the ATMA Board of Directors.

“We are extremely excited to strengthen our partnership with the team at ATMA through this investment. This further solidifies the Company’s strategic position in clinics and partnerships for the deployment of digital therapeutics to drive near-term revenues. ATMA’s team is a true pioneer in the psychedelic therapy industry by growing a global network of group and retreat psychedelic therapy clinics,” said Kelsey Ramsden, President and CEO, MINDCURE. “ATMA’s established clinical footprint gives us the opportunity to deploy our iSTRYM technology, with the intended goal to optimize treatment for ATMA’s patients and obtain the data we need to build iSTRYM into the platform trusted by therapists and patients around the world.”
iSTRYM is an investigating technology that focuses on patient feedback and data-driven insights into the efficacy of treatments in order to assist in the application of more effective and more efficient diagnosis techniques and treatments. It’s a technology that is targeted for both therapists and patients.

As first stated in the LOI on January 12, 2021, MINDCURE’s investment into ATMA will facilitate the syndication of Mind Cure’s psychedelic drug protocols and the use of MINDCURE’s proprietary AI-driven platform, iSTRYM, to optimize treatment for ATMA clients.

“We are thrilled today to welcome a visionary leader like Kelsey to our Board of Directors,” said Vu Tran, Co-CEO of ATMA. “We are eager to get to work with the MINDCURE team to help establish the industry-standard protocols and digital tools to better help patients in need and the therapists that serve them.”

The strategic investment was comprised of a purchase of $350,000 of ATMA’s Series A Preference shares as part of ATMA’s Series A financing. MINDCURE satisfied the aggregate subscription price through the issuance of 796,541 common shares in its capital at an agreed-upon price of $0.4394 per share, being the 10-day volume-weighted average trading price of the common shares on the Canadian Securities Exchange.

About ATMA Journey Centers Inc.

ATMA is a private healthcare company with the mission of delivering effective and innovative healing and transformative experiences that awaken the inner healer and promote a deeper connection with the self, with others, and with the beauty of the world. ATMA was the first private sector service provider in Canada to announce conducting legal psychedelic-assisted therapy for a palliative care patient under the approval of Health Canada’s section 56(1) exemption. Our team members collectively have over 100 years of experience in the disciplines of medicine work, integration, therapy and personal development.

The ATMA Journey Team is comprised of medical professionals, management staff and advocates who believe that psychedelic and non-traditional medicines have an important role to play in the healing and transformation of humankind. We believe that the current approaches to mental and emotional struggles are simply not enough and that psychedelics hold the key to actually resolving the root causes of mental health issues that affect so many. The ATMA Team is deeply committed to creating and delivering the most effective long-term healing and transformation program available.

The Company has entered into an agreement with Psychedelic Finance to provide services relating to social media support and strategic media services for a six month term beginning in April, 2021. The Company has agreed to pay a total of CDN$60,000 for the services to be provided during the term.

About Mind Cure Health (MINDCURE) Inc.

MINDCURE exists as a response to the current mental health crisis and urgent calls for effective treatments. MINDCURE believes in the need to reinvent the mental health care model for patients and practitioners to allow psychedelics to advance into common and accepted care.

MINDCURE is focused on identifying and developing pathways and products that ease suffering, increase productivity, and enhance mental health. MINDCURE is interested in exploring diverse therapeutic areas beyond psychiatry, including digital therapeutics, neuro-supports, and psychedelics, all to improve mental health.

On Behalf of the Board of Directors
Kelsey Ramsden, President & CEO
Phone: 1-888-593-8995

Forward-Looking Information

Certain statements in this news release may constitute “forward-looking information” within the meaning of applicable securities laws (also known as forward-looking statements). Forward-looking information involves known and unknown risks, uncertainties and other factors, and may cause actual results, performance or achievements or industry results, to be materially different from any future results, performance or achievements or industry results expressed or implied by such forward-looking information. Forward-looking information generally can be identified by the use of terms and phrases such as “anticipate”, “believe”, “could”, “estimate”, “expect”, “feel”, “intend”, “may”, “plan”, “predict”, “project”, “subject to”, “will”, “would”, and similar terms and phrases, including references to assumptions. Some of the specific forward-looking information in this news release includes, but is not limited to, statements with respect to: MINDCURE deploying its iSTRYM technology through ATMA clinics; iSTRYM becoming the platform trusted by therapists and patients around the world; and ATMA and MINDCURE establishing the industry-standard protocols and digital tools to better help patients in need and the therapists that serve them.

Forward-looking information is based on a number of key expectations and assumptions made by MINDCURE, including, without limitation: the COVID-19 pandemic impact on the Canadian economy and MINDCURE’s business, and the extent and duration of such impact; no change to laws or regulations that negatively affect MINDCURE’s business; there will be a demand for MINDCURE’s products in the future; no unanticipated expenses or costs arise; MINDCURE will be able to continue to identify products that make them ideal candidates for providing solutions for treating mental health; that the functional mushroom industry will continue to grow; MINDCURE will deploy its iSTRYM technology through ATMA clinics; ATMA and MINDCURE  will establish the industry-standard protocols and digital tools to better help patients in need and the therapists that serve them; and MINDCURE will be able to operate its business as planned. Although the forward-looking information contained in this news release is based upon what MINDCURE believes to be reasonable assumptions, it cannot assure investors that actual results will be consistent with such information.

Forward-looking information is provided for the purpose of presenting information about management’s current expectations and plans relating to the future and readers are cautioned that such statements may not be appropriate for other purposes. Forward-looking information involves significant risks and uncertainties and should not be read as a guarantee of future performance or results as actual results may differ materially from those expressed or implied in such forward-looking information. Those risks and uncertainties include, among other things, risks related to: the impacts of the COVID-19 pandemic on the Canadian economy, MINDCURE’s industry and MINDCURE’s business, which may negatively impact, and may continue to negatively impact, MINDCURE and may materially adversely affect MINDCURE’s investments, results of operations, financial condition, and MINDCURE’s ability to obtain additional equity or debt financing, and satisfy its financial obligations; general economic conditions; future growth potential; competition for mental health and wellness investments MINDCURE may not deploy its iSTRYM technology through ATMA clinics; ATMA and MINDCURE  may not establish the industry-standard protocols and digital tools to better help patients in need and the therapists that serve them; and changes in legislation or regulations. Management believes that the expectations reflected in the forward-looking information contained herein are based upon reasonable assumptions and information currently available; however, management can give no assurance that actual results will be consistent with such forward-looking information. Additional information on the risk factors that could affect MINDCURE can be found under “Risk Factors” in MINDCURE’s final prospectus which is available on SEDAR at www.sedar.com.

The forward-looking information contained herein is expressly qualified in its entirety by this cautionary statement. Forward-looking information reflects management’s current beliefs and is based on information currently available to MINDCURE. The forward-looking information is stated as of the date of this news release and MINDCURE assumes no obligation to update or revise such information to reflect new events or circumstances, except as may be required by applicable law.

United States Advisory
The securities referred to herein have not been and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), may be offered and sold outside the United States to eligible investors pursuant to Regulation S promulgated under the U.S. Securities Act, and may not be offered, sold, or resold in the United States or to, or for the account of or benefit of, a U.S. Person (as such term is defined in Regulation S under the United States Securities Act) unless the securities are registered under the U.S. Securities Act, or an exemption from the registration requirements of the U.S. Securities Act is available. Hedging transactions involving the securities must not be conducted unless in accordance with the U.S. Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any securities, nor shall there be any sale of securities in the state in the United States in which such offer, solicitation or sale would be unlawful.

The CSE has neither approved nor disapproved the contents of this press release and the CSE does not accept responsibility for the adequacy or accuracy of this release.

SOURCE Mind Cure Health Inc.

For further information: Investor Relations: investors@mindcure.com; 1-888-593-8995; Jonathan L. Robinson CFA, Partner, Oak Hill Financial Inc., jrobinson@oakhillfinancial.ca, 416-669-1001

‍